2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3509 Single-cell spatial transcriptomics defines distinct PD-1/PD-L1 axis architecture across EBV-stratified PTLD and non-PTLD DLBCL

Andrew Jay Portuguese, MD, Albert C Yeh, MD2, Bryce N Fukuda3, Minggang Lin4, Elizabeth Donato5, Kikkeri N Naresh, MD, MBBS, FRCPath6, Alexandre V Hirayama, MD7, Jordan Gauthier, MD8, Vikas Dharnidharka9, Cecilia CS Yeung, MD, Professor Pathology10, Christopher Blosser11
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 Rutgers University, New Brunswick, New Jersey, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States
11 University of Washington, Seattle, Washington, United States

Background: Epstein-Barr virus (EBV)-positive and EBV-negative post-transplant lymphoproliferative disorders (PTLD) are biologically distinct. In EBV-positive PTLD, EBV latent membrane protein 1 (LMP1) signaling promotes PD-L1/PD-L2 upregulation and immune evasion, and prior studies found PD-L1 expression in malignant B cells and myeloid cells, as well as monocyte enrichment. In contrast, EBV-negative PTLD more closely resembles diffuse large B-cell lymphoma (DLBCL). However, the cell-specific and spatial organization of the PD-1/PD-L1 axis across EBV-positive PTLD, EBV-negative PTLD, and conventional DLBCL remain poorly defined.

Methods: We used the 380-gene 10x Genomics Xenium Human Immuno-Oncology panel plus a 100-gene custom add-on (480 targets including EBV transcripts) on tissue microarrays from archival diagnostic specimens: 42 PTLD cores from 19 patients (pts; 11 EBV-positive, 8 EBV-negative) and 41 cores from 21 non-PTLD DLBCL samples. PTLD cases included liver (58%), heart (26%), kidney (11%), and pancreas (5%) transplant recipients; biopsies included GI (53%), nodal (26%), or extranodal sites (21%) from 2002-2024. Proseg segmentation and filtering (≥20 transcripts and 10 genes/cell) yielded 1,061,904 cells: 318,284 EBV-positive PTLD, 138,132 EBV-negative PTLD, and 605,488 control DLBCL cells. Canonical-marker rules assigned cell identities; hematopathologists reviewed concordance with matched H&E sections. High checkpoint expression was defined using lineage-specific PTLD 90th percentile thresholds. Checkpoint expression was summarized by cell type; within-core 10-nearest-neighbor graphs quantified checkpoint-cell adjacency. Gene-program scores averaged listed normalized genes; higher values indicated more lymphoma-like or proliferative transcription. Replicate cores were collapsed to the pt/sample level before statistical testing. Wilcoxon tests assessed programs and spatial metrics. All-cell and malignant B-cell pseudobulk differential expression used Limma-voom with Benjamini-Hochberg correction.

Results: Broad lineage composition and global interfaces did not differ after false-discovery correction. EBV-positive PTLD had higher B-cell PD-L1 expression than EBV-negative PTLD (median sample-level mean normalized expression, 0.0461 vs 0.0168; q=0.016) and control DLBCL (0.0461 vs 0.0230; q=0.016). Malignant B-cell PD-L2 expression was also higher in EBV-positive PTLD than in EBV-negative PTLD and control DLBCL (EBV-positive 0.0462, EBV-negative 0.0226, control 0.0268; q=0.016 and q=0.024, respectively). Control DLBCL had a higher fraction of PD-L1-high myeloid cells than EBV-positive PTLD (0.171 vs 0.089; q=0.016) and more PD-1-high T cells adjacent to PD-L1-high myeloid cells (0.267 vs 0.107; q=0.036). Among 9 EBV-positive PTLD pts evaluable for within-pt EBER-detected versus EBER-undetected analysis, EBER-detected malignant B cells had higher adjusted PD-L1 (median coefficient, 0.0072; q=0.049).

The curated B-cell lymphoma-associated program (BCL6, CD40, CD83, CXCR5, PAX5, TCL1A, TOX) was higher in EBV-negative than EBV-positive malignant B cells (median standardized pt score, 0.137 vs -0.907; q=0.024); control DLBCL scored 0.630 (vs EBV-positive, q=0.001). The malignant B-cell proliferation-associated score (MKI67, TOP2A, PCNA, MYC) trended higher in EBV-negative than EBV-positive PTLD (q=0.055), while EBV-positive PTLD scored lower than control DLBCL (q=0.010). Pseudobulk confirmed enrichment of latent and lytic-cycle EBV transcripts (EBER1/2, LMP1/2, EBNA2/3B/3C, BZLF1) in EBV-positive PTLD. EBV-positive tissue expressed higher IL12RB2, whereas EBV-negative tissue showed higher TCL1A overall (EBV-positive vs EBV-negative log2FC=-4.54; q=0.004) and higher TCL1A and SPIB within malignant B cells (q=0.002 and q=0.048). Relative to EBV-positive PTLD, control DLBCL was enriched for B-cell/lymphoma genes including CXCR5, PAX5, CD37, SPIB, MS4A1, CD40, and CD83 (all q≤0.002).

Conclusions: EBV-positive PTLD exhibited higher PD-L1/PD-L2 and latent/lytic EBV transcripts in malignant B cells, whereas non-PTLD DLBCL showed a myeloid-centered PD-L1 program with greater adjacency of PD-1-high T cells to PD-L1-high myeloid cells. EBV-negative PTLD retained a more DLBCL-like B-cell program, including higher TCL1A/SPIB and a trend toward greater proliferation. These findings define distinct EBV-associated checkpoint architectures, supporting EBV-stratified biomarker development and future immunotherapeutic investigation

Andrew Jay Portuguese, MD: Pfizer - Research Funding; Regeneron - Research Funding; Karyopharm - Consultancy (Includes expert testimony)